Last updated: July 21, 2026
Executive summary: RDC Liquidating Trust filed a fresh patent infringement action against Teva Pharmaceutical Industries (case no. 1:24-cv-11320). The record needed to produce a complete, citation-grade infringement-and-expiration analysis is not available in the supplied inputs. Per operating constraints, no partial or guess-based claim mapping, Orange Book status conclusions, or timeline assertions are provided.
What patent infringement claims does RDC Liquidating Trust v. Teva (1:24-cv-11320) allege?
Answer (required for accuracy): Not stated in the provided information.
Which patents are asserted in the complaint?
Not provided.
Which drug product and dosage form are accused?
Not provided.
What infringement theory is pleaded (ANDA, literal infringement, equivalents, inducement/contribution)?
Not provided.
What is the procedural posture of RDC Liquidating Trust v. Teva (1:24-cv-11320)?
Answer (required for accuracy): Not stated in the provided information.
When was the case filed and what court is it in?
Only the docket identifier “1:24-cv-11320” is provided, with no filing date, division, judge, or court confirmation in the supplied inputs.
Has Teva moved to dismiss, sought claim construction, or filed an early dispositive motion?
Not provided.
Has there been a scheduling order, Markman date, or amended complaint?
Not provided.
Is this case an ANDA Paragraph IV or another Hatch-Waxman route?
Answer (required for accuracy): Not provided.
Do the allegations tie to a specific Orange Book listing?
Not provided.
Are biosimilar or biologics pathways involved?
Not provided.
When does the asserted patent estate expire, and what exclusivity windows might apply?
Answer (required for accuracy): Not provided.
What are the earliest expiration and any pediatric extensions?
Not provided.
Any terminal disclaimers or continuation effects?
Not provided.
What does Teva’s defense typically include in similar suits, and what is Teva likely challenging here?
Answer (required for accuracy): Not provided.
Non-infringement positions
Not provided.
Invalidity theories (anticipation, obviousness, lack of enablement, indefiniteness)
Not provided.
Enforceability defenses (inequitable conduct, prosecution history, standing)
Not provided.
What settlement posture signals risk in RDC Liquidating Trust v. Teva (1:24-cv-11320)?
Answer (required for accuracy): Not provided.
Has there been a standstill, covenant not to sue, or consent judgment?
Not provided.
Any public dispute over launch dates or market entry timing?
Not provided.
How strong is the patent estate for Teva’s product based on the asserted claims?
Answer (required for accuracy): Not provided.
Are claims product claims, method-of-use claims, or both?
Not provided.
Are formulation claims asserted (e.g., extended-release, solid-state forms, polymorphs)
Not provided.
Are there prosecution-history features (narrowing amendments, disclaimer) that limit claim scope?
Not provided.
What generic entry risks exist for Teva if RDC wins in 1:24-cv-11320?
Answer (required for accuracy): Not provided.
Potential remedies
Not provided.
Injunction scope and whether it is product-level or claim-limited
Not provided.
How does RDC Liquidating Trust v. Teva compare with other RDC trust actions against generics?
Answer (required for accuracy): Not provided.
Consistency of asserted patent portfolios across cases
Not provided.
Forum and procedural patterns
Not provided.
Key Takeaways
No litigation-specific assertions can be validated from the provided input. A complete litigation summary for RDC Liquidating Trust v. Teva (1:24-cv-11320) requires the complaint allegations and the asserted patent list, which are not included.
FAQs
- What patents are asserted in RDC Liquidating Trust v. Teva Pharmaceutical Industries (1:24-cv-11320)? Not provided.
- Is 1:24-cv-11320 tied to a specific ANDA and Paragraph IV certification? Not provided.
- What is Teva’s most likely invalidity theory in this case? Not provided.
- What is the earliest possible injunction or launch-impact date in the docket? Not provided.
- Which court judge and district division handle 1:24-cv-11320? Not provided.
References
No sources were provided in the prompt to cite.
